Company Filing History:
Years Active: 1997-2000
Cheryl A Alaimo: Pioneering Innovation in Neurokinin Antagonists
Introduction
Cheryl A Alaimo, a prominent inventor based in Somerset, NJ, has made significant contributions to the field of neurokinin antagonists. With a total of 4 patents to her name, Alaimo has proven to be a trailblazer in the pharmaceutical industry.
Latest Patents
Her latest patents include groundbreaking inventions such as "Substituted oximes as neurokinin antagonists" and "Substituted oximes, hydrazones and olefins as neurokinin antagonists." These patents showcase her expertise in developing compounds that hold immense promise in the treatment of neurological disorders.
Career Highlights
Alaimo's stellar career is marked by her affiliation with Schering Corporation, a renowned pharmaceutical company known for its cutting-edge research and development. As a key member of the team, she has been instrumental in driving innovation and pushing the boundaries of scientific discovery.
Collaborations
Throughout her career, Alaimo has worked closely with accomplished colleagues such as Nicholas I Carruthers and Gregory A Reichard. Their collaborative efforts have led to breakthroughs in the field of neurokinin antagonists, setting new standards for excellence in pharmaceutical research.
Conclusion
In conclusion, Cheryl A Alaimo stands out as a visionary inventor who continues to shape the future of medicine through her pioneering work in neurokinin antagonists. Her dedication to innovation and scientific excellence serves as an inspiration to aspiring inventors and researchers worldwide.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.